Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung von Essstörungen und Adipositas

  • Chapter
  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

  • 7991 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung von Essstörungen und Adipositas im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Appolinario JC, Nardi AE, McElroy SL (2019) Investigational drugs for the treatment of binge eating disorder (BED): an update. Expert Opin Investig Drugs 28(12):1081–1094

    Article  CAS  Google Scholar 

  • Attia E, Steinglass JE, Walsh BT et al (2019) Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. Am J Psychiatry 176:449–456

    Article  Google Scholar 

  • AWMF Online (2019) S3-Leitlinie „Diagnostik und Therapie der Essstörungen“. https://www.awmf.org/leitlinien/detail/ll/051-026.html

  • Blanchet C, Guillaume S, Bat-Pitault F et al (2019) Medication in AN: a multidisciplinary overview of meta-analyses and systematic reviews. J Clin Med 25(8):278

    Article  Google Scholar 

  • Chao AM, Wadden TA, Walsh OA et al (2019) Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day. Clin Obes 9:12340

    Article  Google Scholar 

  • Durrer Schutz D, Busetto L, Dicker D et al (2019) European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts 12:40–66

    Article  Google Scholar 

  • Himmerich H, Treasure J (2018) Psychopharmacological advances in eating disorders. Expert Rev Clin Pharmacol 11:95–108

    Article  CAS  Google Scholar 

  • Himmerich H, Minkwitz J, Kirkby KC (2015) Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord Drug Targets 15(4):252–260

    Article  CAS  Google Scholar 

  • Himmerich H, Joaquim M, Bentley J et al (2018) Psychopharmacological options for adult patients with anorexia nervosa: the patients’ and carers’ perspectives. CNS Spectr 23:251–252

    Article  Google Scholar 

  • Himmerich H, Bentley J, Kan C, Treasure J (2019) Genetic risk factors for eating disorders: an update and insights into pathophysiology. Ther Adv Psychopharmacol 9:2045125318814734

    Article  CAS  Google Scholar 

  • Larsen JR, Vedtofte L, Jakobsen MSL et al (2017) Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 74:719–728

    Article  Google Scholar 

  • LEADER Steering Committee, LEADER Trial Investigators, Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322

    Article  Google Scholar 

  • McElroy SL, Hudson JI, Mitchell JE et al (2015) Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry 72:235–246

    Article  Google Scholar 

  • McElroy SL, Guerdjikova AI, Mori N, Romo-Nava F (2019) Progress in developing pharmacologic agents to treat bulimia nervosa. CNS Drugs 33:31–46

    Article  Google Scholar 

  • Qasim A, Turcotte M, de Souza RJ et al (2018) On the origin of obesity: identifying the biological, environmental and cultural drivers of genetic risk among human populations. Obes Rev 19:121–149

    Article  CAS  Google Scholar 

  • le Roux CW, Astrup A, Fujioka K et al (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389:1399–1409

    Article  Google Scholar 

  • Safer DL, Adler S, Dalai SS et al (2020) A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa. Int J Eat Disord 53:266–277

    Article  Google Scholar 

  • Singh AK, Singh R (2020) Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol 13:53–64

    Article  CAS  Google Scholar 

  • Siskind DJ, Russell AW, Gamble C et al (2018) Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes Obes Metab 20:1050–1055

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. London, Großbritannien

    Prof. Dr. med. Hubertus Himmerich

  2. Mainz, Deutschland

    Otto Benkert

Authors
  1. Prof. Dr. med. Hubertus Himmerich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Germany

    Otto Benkert

  2. Klinik für Psychiatrie und Psychotherapie, ehemals Universitäts-Klinikum München Campus Innenstadt, München, Germany

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Himmerich, H., Benkert, O. (2021). Medikamente zur Behandlung von Essstörungen und Adipositas. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-61753-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-61753-3_9

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-61752-6

  • Online ISBN: 978-3-662-61753-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation